Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to ...

Moderna’s latest flu vaccine, based on similar mRNA technology integrated in its COVID-19 shot, displayed optimistic outcomes ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

Moderna shares rose on the increased effectiveness of its flu vaccine in late-stage trials, bring the biotech company closer ...

Opioid addicts covered by Medicare and Medicaid are less likely to receive the mental health and substance use treatment that ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

Covid has largely dropped out of the headlines, but the virus that causes it is still circulating. We ask what we should know about a new variant of SARS-CoV-2, the state of the Covid pandemic in 2025 ...

Terrana is aiming to have commercially available products in the next few years, pending regulatory approval, that can be applied as sprayables or seed treatments. And the company says its RNA-based ...